STUDY AGREEMENT TEMPLATE FOR A REQUESTED ECONOMIC PLANNING STUDYStudy Agreement • August 29th, 2022 • New York
WHEREAS, Requestor has submitted a completed Requested Economic Planning Study Request Form, dated , (“Request Form”) and a $25,000 deposit to the NYISO for the NYISO to conduct a Requested Economic Planning Study pursuant to Section 31.3.3 of Attachment Y to the OATT; and
APPENDIX B STANDARD LARGE GENERATOR INTERCONNECTION PROCEDURES (LGIP) including STANDARD LARGE GENERATOR INTERCONNECTION AGREEMENT (LGIA) Standard Large Generator Interconnection Procedures (LGIP) (Applicable to Generating Facilities that exceed 20 MW)Study Agreement • May 5th, 2020
System Impact Study AgreementStudy Agreement • December 13th, 2020 • Minnesota
THIS AGREEMENT is made and entered into this day of 20 by and between , (“Interconnection Customer”), and , a municipal utility existing under the laws of the State of Minnesota, (“Area EPS Operator”). Interconnection Customer and Area EPS Operator each may be referred to as a “Party,” or collectively as the “Parties.”
ContractStudy Agreement • February 21st, 2024
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ concluded according to Section 1746(2) of Act No. 89/2012 Sb. Civil Code and Section 12(2) of Decree No. 226/2008 Sb. on Good Clinical Practice and DetailedConditions of Clinical Trials on Medicinal Products, as amended. uzavřená podle § 1746 odst. 2 zákona č. 89/2012 Sb. občanského zákoníku a § 12 odst. 2 vyhlášky č. 226/2008 Sb., o správné klinické praxi a bližších podmínkáchklinického hodnocení léčivých přípravků, ve znění pozdějších předpisů. AbbVie s.r.o., Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by Branislav Trutz, MD, General Manager and Executive ("AbbVie") desires to retain Nemocnice Jihlava, p.o., Vrchlického 59, 586 33 Jihlava, Czech Republic, ID: 000 90 638, VAT ID: CZ00090638, represented by MUDr.Lukáš Velev, MHA, Director (the “Institution”) and (the “Principal Investigator”) to conduct a clinical study (the “Study”) in relatio
ContractStudy Agreement • December 27th, 2023 • New York
New York Independent System Operator, Inc. - NYISO Tariffs - Open Access Transmission Tariff (OATT) - 30 OATT Attachment X - Standard Large Facility Interconnecti - 30.11 OATT Att X Standard Large Generator Interconnection Ag
Federal Work-Study Off-Campus Agreement and Job Placement Form Award Year 2022-2023Study Agreement • October 29th, 2021
In order for a Union Institute & University (Union) learner to be employed off-campus in a Federal Work-Study (FWS) position, the University and the Federal, State, or local public agency or private non-profit organization that employs the learner must enter into an agreement.
STUDY AGREEMENT NoStudy Agreement • June 2nd, 2020
THIS INTERCONNECTION LEVEL 3 SYSTEM IMPACT STUDY AGREEMENTStudy Agreement • May 9th, 2017 • Utah
WHEREAS, Interconnection customer is proposing to develop a Generating facility or generating capacity addition to an existing Generating facility consistent with the Interconnection request completed by Interconnection customer on ; and,
ContractStudy Agreement • October 25th, 2022
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ concluded according to Section 1746(2) of Act No. 89/2012 Sb. Civil Code and Section 12(2) of Decree No. 226/2008 Sb. on Good Clinical Practice and Detailed Conditions of Clinical Trials on Medicinal Products, as amended. uzavřená podle § 1746 odst. 2 zákona č. 89/2012 Sb. občanského zákoníku a § 12 odst. 2 vyhlášky č. 226/2008 Sb., o správné klinické praxi a bližších podmínkách klinického hodnocení léčivých přípravků, ve zněnípozdějších předpisů. AbbVie s.r.o., Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by Branislav Trutz, MD, General Manager and Executive ("AbbVie") desires to retain Nemocnice Na Bulovce, Budínova 67/2 180 81 Praha 8 – Libeň, Czech Republic, ID: 00064211; VAT ID: CZ0006421, Director: MUDr. Tomáš Podlešák, Deputy Director for Medical-Preventive Treatment, based upon delegation of powers (the “Institution”) to conduct a clinic
Transmission System Impact Study AgreementStudy Agreement • December 13th, 2020 • Minnesota
THIS AGREEMENT is made and entered into this day of 20 by and between , (“Interconnection Customer”), and , a municipal utility existing under the laws of the State of Minnesota, (“Area EPS Operator”), and
ContractStudy Agreement • September 11th, 2017
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ Protocol No: AM-111-CL-13-01 (“theProtocol”) Protokol č.: AM-111-CL-13-01(“Protokol”) Investigational medicinal product (“the IMP”): Hodnocený léčivý přípravek („Hodnocené léčivo“): Sponsor: Zadavatel: Auris Medical AG, , Falknerstasse 4, 4001 Basel, Switzerland acting by its legally authorized representative / jednající prostřednictvím svého zástupce: hereinafter “the Sponsor”, dále jen „Zadavatel“, represented upon the power of attorney (Appendix No. 5) given to: zastoupený na základě plné moci (Příloha č.5) udělené společnosti: EastHORN Clinical Services in CEE Limited Kyvelis 7, Office 102, P.C. 1087, Nicosia, Cyprus / KyprCourt Registration Number: HE253002 Tax ID / DIČ: CY10253002Urepresented by Malgorzata Szerszeniewska, MD, Executive Head /zastoupená MUDr.Malgorzata Szerszeniewska, jednatelem and a CRO: CRO: EastHORN Clinical Services in CEE LimitedKyvelis 7, Office 102, P.C. 1087, Nicosia, Cyprus / Kypr Court Registrat
STANDARD LARGE GENERATOR INTERCONNECTION AGREEMENT (LGIA)Study Agreement • December 14th, 2021
Appendix 1 – Interconnection Request for a Large Generating Facility Appendix 2 – Interconnection Feasibility Study Agreement
EAN COVID-19 Registry – Study Agreement Participating SiteStudy Agreement • March 2nd, 2023
THIS INTERCONNECTION LEVEL 3 FACILITIES STUDY AGREEMENTStudy Agreement • May 9th, 2017 • Utah
WHEREAS, Interconnection customer is proposing to develop a Generating facility or generating capacity addition to an existing Generating facility consistent with the Interconnection request completed by Interconnection customer on ; and,
ContractStudy Agreement • October 7th, 2021
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ concluded according to Section 1746(2) of Act No. 89/2012 Sb. Civil Code and Section 12(2) of Decree No. 226/2008 Sb. on Good Clinical Practice and DetailedConditions of Clinical Trials on Medicinal Products, as amended. uzavřená podle § 1746 odst. 2 zákona č. 89/2012 Sb. občanského zákoníku a § 12 odst. 2 vyhlášky č. 226/2008 Sb., o správné klinické praxi a bližších podmínkáchklinického hodnocení léčivých přípravků, ve znění pozdějších předpisů. AbbVie s.r.o., Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by Branislav Trutz, MD, General Manager and Executive ("AbbVie") desires to retain Fakultní nemocnice Plzeň, Edvarda Beneše 1128/13, 305 99 Plzeň, Czech Republic, ID: 00669806 VAT ID: CZ00669806, represented by Director MUDr. Václav Šimánek, Ph.D (the “Provider of Medical Services”) to conduct a clinical study (the “Study”) in relation to Venet
ContractStudy Agreement • April 24th, 2023
CLINICAL STUDY AGREEMENT Entered into by Parties in accordance with Section 269 Par. 2 Act No. 513/ 1991 Comercial Code ofSlovak Republic as amended ZMLUVA O KLINICKOM SKÚŠANÍ Uzatvorená Zmluvnými stranami podľa § 269 odst.2 zákona č. č.513/1991 Zb..Obchodný zákonníkSlovenskej republiky v platnom znení AbbVie s.r.o., Karadžičova 10, 821 08 Bratislava, Slovak Republic, RN: 46640231, RN for tax: 203529057, RN for VAT: SK2023529057, Legal Representative: Branislav Trutz, M.D., Company is registered in Trade Register of District Court Bratislava I. Part Sro, insertion no. 81375/B, date of registration 11.05.2012 (hereinafter also referred to as "AbbVie") is entering into agreement with Fakultná nemocnica s poliklinikou Nové Zámky, Slovenská ulica 11A, 940 34 Nové Zámky, Slovak Republic, RN: 1733611, State budgetary organization, registered in Slovak Statistical Register and in Trade register of District Court Nové Zámky under No. 404-9729 (hereinafter also referred to as “Institution”) to
Kansas 4-H Individual Study AgreementStudy Agreement • October 20th, 2020
Kansas 4-H believes that participation in an organized 4-H club is the preferred method of involvement for members, but acknowledges that there are sometimes extenuating circumstances that may make an independent 4-H membership a viable way to still engage in 4-H Youth Development learning. Any youth who wishes to be an Independent 4-H member must complete an Individualized Study Agreement which will be reviewed and approved by the 4-H Agent. The study agreement shall be filed with the Extension Office before enrollment is to be approved.
STUDY AGREEMENT FOR EVALUATION OF PUBLIC POLICY TRANSMISSION PROJECTSStudy Agreement • March 23rd, 2017 • New York
THIS AGREEMENT is made and entered into this day of _, 20 by and between , a organized and existing under the laws of the State of (“Developer”), and the New York Independent System Operator, Inc., a not-for-profit corporation organized and existing under the laws of the State of New York
STUDY AGREEMENTStudy Agreement • July 30th, 2019
INTERCONNECTION AGREEMENT (GIA)Study Agreement • October 30th, 2017 • Missouri
Appendix 3 AECI Transmission Confidentiality and Non-Disclosure Agreement Appendix 4 AECI Generator Interconnection Agreement
NON-INTERVENTIONAL STUDY AGREEMENTStudy Agreement • May 16th, 2023
This non-interventional study agreement (“Agreement”) is entered into as the last date of the signature below (“Effective Date”) between
Higher Education Student Study Agreement 2023-24Study Agreement • July 27th, 2023 • England and Wales
This Study Agreement is applicable to all students of higher education at New College Swindon University Centre (Queens Drive Campus and North Star Campus including HE provision within the Institute of Technology) referred to herein as ‘the College’.
ContractStudy Agreement • March 3rd, 2022
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ concluded according to Section 1746(2) of Act No. 89/2012 Sb. Civil Code and Section 12(2) of Decree No. 226/2008 Sb. on Good Clinical Practice and Detailed Conditions of Clinical Trials on Medicinal Products, asamended. uzavřená podle § 1746 odst. 2 zákona č. 89/2012 Sb. občanského zákoníku a § 12 odst. 2 vyhlášky č. 226/2008 Sb., o správné klinické praxi a bližších podmínkách klinického hodnocení léčivých přípravků, ve zněnípozdějších předpisů. AbbVie s.r.o., Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by Branislav Trutz, MD, General Manager and Executive ("AbbVie") desires to retain Fakultní nemocnice Ostrava, 17. Listopadu 1790, 708 52 Ostrava - Poruba,Czech Republic, ID: 008 43 989, VAT ID: CZ00843989,Letter of Establishment by Ministry of Health of Czech Republic, dated as of 25 November 1990, reg.no. OP-054- 25.11.90, represented by MUDr
EX-10.9 8 d772541dex109.htm MASTER CLINICAL STUDY AGREEMENT, MEMORIAL SLOAN- KETTERING CANCER CENTER [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment...Study Agreement • May 5th, 2020 • New York
This Master Clinical Study Agreement is entered into as of November 21, 2013 (the “Effective Date”), by and between Memorial Sloan-Kettering Cancer Center (“MSKCC”), a New York nonprofit corporation, and Juno Therapeutics, Inc. (“Sponsor”), a Delaware corporation.
ContractStudy Agreement • June 19th, 2018
CLINICAL STUDY AGREEMENT – COMPASS SMLOUVA O PROVEDENÍ KLINICKÉ STUDIE – COMPASS This Site Agreement for the performance of a clinical trial (hereinafter the “Agreement”) is entered into and effective this 28th day of January 2015 (“Effective Date”) between Fakultní Nemocnice Olomouc, with its principal place of business atI. P. Pavlova 6 77520 Olomouc Czech RepublicCompany identification number: 00098892 VAT number: CZ00098892Represented by doc. MUDr. Roman Havlík, Ph.D., hospital director(hereinafter the “Institution”) Tato smlouva o provedení klinické studie (dále jen„Smlouva“) se uzavírá a nabývá účinnosti dne 28 měsíce leden 2015 („Datum nabytí účinnosti“) mezi Fakultní Nemocnicí Olomouc s hlavním sídlem na adreseI. P. Pavlova 6 77520 Olomouc Česká republika IČO: 00098892DIČ: CZ00098892Zastoupená doc. MUDr. Romanem Havlíkem, Ph.D., ředitelem(dále jen „Instituce“) -and- -a- Bayer Pharma AG, Muellerstrasse 178, 13353 Berlin, Germany (hereinafter “Bayer”) společností Bayer Pharma AG,
Independent Study Agreement FormStudy Agreement • August 12th, 2020
Use this form to petition and provide details for an EH 300 Independent Study. Review this form with the instructor sponsoring the Independent Study, your Faculty Advisor, and Barbara Zuckerman, Academic Administrator/ Assistant Director of Faculty and Academic Affairs, and obtain their signatures. Return the completed form to Barbara (bzuckerm@hsph.harvard.edu) during the registration period for the semester of the Independent Study.
ContractStudy Agreement • May 28th, 2022
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ Protocol No: AZT-001 (“the Protocol”) Protokol č.: AZT-001 (“Protokol”) Investigational medicinal product (“the IMP”): ALZT-OP1 Hodnocený léčivý přípravek („Hodnocené léčivo“): ALZT-OP1 Sponsor: Zadavatel: AZTherapies, Inc., 501 Boylston Street, Suite 6102, Boston, MA 02116, USA acting by its legally authorized representative / AZTherapies, Inc., 501 Boylston Street, Suite 6102, Boston, MA 02116, USA jednající prostřednictvím svého zástupce: hereinafter “the Sponsor”, dále jen „Zadavatel“, represented upon the power of attorney given to: zastoupený na základě plné moci udělené společnosti: EastHORN Clinical Services in CEE Limited Kyvelis 7, Office 102,. P.C. 1087, Nicosia, Cyprus / KyprCourt Registration Number: HE253002 Tax ID / DIČ: CY10253002Urepresented by Malgorzata Szerszeniewska, MD, Executive Head /zastoupená MUDr. Malgorzata Szerszeniewska, jednatelem and a CRO: CRO: EastHORN Clinical Services in CEE LimitedKyvelis 7,
STUDY AGREEMENT FOR AN ADDITIONAL CARIS STUDYStudy Agreement • April 12th, 2010 • New York
THIS AGREEMENT is made and entered into this day of , 20 by and between , a organized and existing under the laws of the State of , (“Requestor”), and the New York Independent System Operator, Inc., a not-for-profit corporation organized and existing under the laws of the State of New York (“NYISO”). Requestor and NYISO each may be referred to as a “Party,” or collectively referred to as the “Parties.”
CLINICAL STUDY AGREEMENTStudy Agreement • April 26th, 2022
The UNIVERSITY OF THE PHILIPPINES, the national university of the Philippines, created through Act No. 1870 and operating under Republic Act No. 9500, represented herein by the Chancellor of the University of the Philippines Manila, DR. CARMENCITA D. PADILLA, with office address at the 8th Floor, RCB Building, Philippine General Hospital, Manila, hereinafter referred to as the “UNIVERSITY” ;
GFID 5824 Coronus Energy Corp. - Coronus Apple Valley East 1, LLC RULE 21 INDEPENDENT STUDY PROCESS STUDY AGREEMENTStudy Agreement • February 14th, 2013 • Coronus Solar Inc. • Services-educational services
THIS INDEPENDENT STUDY PROCESS STUDY AGREEMENT ("AGREEMENT") is made and entered into this ____ day of ________________, 2012 by and Coronus Apple Valley East 1, LLC, a limited liability company organized and existing under the laws of the State of Delaware, a subsidiary of Coronus Energy Corp., ("Applicant,") and Southern California Edison Company, a corporation existing under the laws of the State of California ("SCE" or "Distribution Provider"). Applicant and Distribution Provider each may be referred to as a "Party," or collectively as the "Parties."
CLINICAL STUDY AGREEMENTStudy Agreement • November 21st, 2018
The UNIVERSITY OF THE PHILIPPINES, the national university of the Philippines, created through Act No. 1870 and operating under Republic Act No. 9500, represented herein by the Chancellor of the University of the Philippines Manila, DR. CARMENCITA D. PADILLA, with office address at the 8th Floor, RCB Building, Philippine General Hospital, Manila, hereinafter referred to as the “INSTITUTION” ;
Santa Paula Unified School District Independent Study AgreementStudy Agreement • August 14th, 2023
Home Phone: Cell Phone: Parent Email: Duration of Agreement Beginning Date: Ending Date: Program Placement - Please circle all that apply: General Ed / Special Ed / IEP / RSP / Speech / 504 / SDC / OT / APE / Intermediate / Elementary
STUDY AGREEMENT FOR EVALUATION OF PROPOSED TRANSMISSION SOLUTION TO A RELIABILITY NEEDStudy Agreement • August 4th, 2014 • New York
THIS AGREEMENT is made and entered into this day of _, 20 by and between , a organized and existing under the laws of the State of , (“Developer,”), and the New York Independent System Operator, Inc., a not-for-profit corporation organized and existing under the laws of the State of New York (“NYISO”). Developer and NYISO each may be referred to as a “Party,” or collectively as the “Parties.”
STUDY AGREEMENTStudy Agreement • June 8th, 2016
(the Host and the Funding Partner hereinafter collectively referred to as the “Parties” and individually referred to as “Party”).
ContractStudy Agreement • November 10th, 2017
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉ STUDII This Clinical Study Agreement (the "Agreement") is made and entered into by and between: Tato smlouva o klinické studii (dále jen„smlouva“) je uzavřena mezi: Všeobecnou fakultní nemocnicí v Praze, U Nemocnice 499/2, 128 08 Prague 2, Czech Republic, ID: 00064165, VAT: CZ00064165,represented by Mgr. Danoa Jurásková, Ph.D.., MBA, director (the “Institution”) Všeobecnou fakultní nemocnicí v Praze, U Nemocnice 499/2, 128 08 Praha 2, Česká republika, IČO: 00064165, DIČ: CZ00064165,zastoupená Mgr. Danou Juráskovou, Ph.D.., MBA, ředitelkou (dále jen „zdravotnické zařízení“) and a (the“Investigator”) Prof. MUDr. Ivanem Špičkou, CSc., Rošovická 347/1, Praha 9, Koloděje, Česká republika (dále jen „zkoušející“) and a Karyopharm Therapeutics Inc., a Delaware Corporation with a place of business at 85 Wells Ave. Newton MA 02459 USA, ID: 4637137,represented by Sharon Shacham (“Sponsor”) zadavatelem Karyopharm Therapeutics Inc., spole
